T-cell biomarkers for risk of progressive multifocal leukoencephalopathy with natalizumab

Takeaway

  • The number and percentage of whole blood CD8+ CD62L- CD45RA- effector memory T cells were significantly increased in natalizumab-treated multiple sclerosis (MS) patients, with the greatest increase observed in the group at high versus low risk of progressive multifocal leukoencephalopathy (PML). However, CD4+ CD62L+ T-cell counts did not differ across PML risk groups in natalizumab-treated patients.

Why this matters

  • Early studies of cryopreserved T cells from people treated with natalizumab have suggested that the number of CD4+ CD62L+ T cells decreases before PML develops.

    • CD62L is an important surface adhesion molecule which allows T cells to recirculate into secondary lymphoid organs such as lymph nodes.

  • The current study indicates that phenotyping CD8+, as opposed to CD4+, peripheral T cells might be more informative for assessing PML risk in natalizumab-treated MS patients.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.